Healthcare Business News

Approval of U.S.' first anthrax anti-toxin hailed as 'monumental step forward'

By Paul Barr
Posted: December 15, 2012 - 11:15 am ET

Nicole Lurie, HHS assistant secretary, applauded the Food and Drug Administration's approval of the U.S.' first anthrax anti-toxin.

Lurie called the approval “a monumental step forward” in preparing for the health effects of bioterrorism, in an HHS news release.

The FDA approval of the injectable anti-toxin, developed under the federal government's biodefense program Project Bioshield, will give people exposed to inhaled anthrax a treatment designed to limit the symptoms, according to the release. Antibiotics, which are used to treat the infection, do not limit the symptoms, according to the release.

Advertisement | View Media Kit


The drug, called Raxibacumab, was developed by Human Genome Sciences, a GlaxoSmithKline company, in conjunction with HHS' Biomedical Advanced Research and Development Authority, according to the FDA.

What do you think?

Share your opinion. Send a letter to the Editor or Post a comment below.

Post a comment

Loading Comments Loading comments...



Switch to the new Modern Healthcare Daily News app

For the best experience of on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.